Cs Diagnostics CORP 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
OTC.Pink
CS Diagnostics Corp. converted all Series B Preferred Stock held by affiliates into 112.65 million common shares to streamline its capital structure and enable consolidated financial reporting by year-end 2025.
OTC.Pink
CS Diagnostics Corp. filed an 8-K report detailing its focus on innovative medical solutions, particularly the CS Protect Hydrogel for radiation therapy.